Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase United States Patent 05409930

05409930 is referenced by 133 patents and cites 8 patents.

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.

Title
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
Application Number
698420
Publication Number
5409930
Application Date
November 8, 1993
Publication Date
April 25, 1995
Inventor
Michael R Myers
Reading
PA, US
Paul E Persons
King of Prussia
PA, US
Martin P Maquire
King of Prussia
PA, US
Alfred P Spada
Lansdale
PA, US
Agent
Raymond S Parker III
Martin F Savitzky
James A Nicholsen
Assignee
Rhone Poulenc Rorer Pharmaceuticals
PA, US
IPC
A01N 43/58
A61K 31/495
View Original Source

Citations: 133 (view full list)

  1. James Doherty
    Clifton John Blankley, Annette Marian Doherty, James Marino Hamby, Robert Lee Panek, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Cleo Connolly: 6-Aryl pyrido�2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation. Charles W Ashbrook, March 31, 1998: US05733913 (64 worldwide citation)
  2. James Doherty
    Clifton John Blankley, Diane Harris Boschelli, Annette Marian Doherty, James Marino Hamby, Sylvester Klutchko, Robert Lee Panek: Pyrido�2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Warner Lambert Company, Charles W Ashbrook, March 31, 1998: US05733914 (48 worldwide citation)
  3. James Doherty
    Clifton J Blankley, Diane H Boschelli, Annette M Doherty, James M Hamby, Sylvester Klutchko, Robert L Panek: Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Warner Lambert Company, Charles W Ashbrook, April 15, 1997: US05620981 (42 worldwide citation)
  4. Michael R Myers, Wei He, Alfred P Spada, Martin P Maguire: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases. Aventis Pharmaceuticals Products, Irving Newman, January 30, 2001: US06180632 (215 worldwide citation)
  5. Wei He, Michael R Myers, Alfred P Spada: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases. Aventis Pharmaceuticals Products, Irving Newman, Peter Butch, June 12, 2001: US06245760 (195 worldwide citation)
  6. Michael R Myers, Alfred P Spada, Paul E Persons, Martin P Maguire: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinases. Aventis Pharmaceuticals Product, Irving Newman, Peter Butch, December 12, 2000: US06159978 (182 worldwide citation)
  7. Mark E Fraley, Kenneth L Arrington, Mark T Bilodeau, George D Hartman, William F Hoffman, Yuntae Kim, Randall W Hungate: Tyrosine kinase inhibitors. Merck & Co, J Antonio Garcia Rivas, Mark R Daniel, October 23, 2001: US06306874 (48 worldwide citation)
  8. Andrew Peter Thomas, Craig Johnstone, Laurent Francois Andre Hennequin: Quinazoline derivatives as VEGF inhibitors. Zeneca, Pillsbury Madison & Sutro, Intellectual Property Group, February 6, 2001: US06184225 (46 worldwide citation)
  9. Andrew Peter Thomas, Jean Jacques Marcel Lohmann, Laurent Francois Andre Hennequin, Patrick Ple: Oxindole derivatives. Zeneca, Pillsbury Winthrop, July 24, 2001: US06265411 (45 worldwide citation)
  10. Neill A Giese, Nathalie Lokker, Alan M Laibelman, Robert M Scarborough: Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases. COR Therapeutics, Cooley Godward, June 29, 1999: US05916908 (44 worldwide citation)

References: 8

  1. George Y Lesher, Chester J Opalka Jr, Donald F Page, Ruthann M McGarry: Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones. Sterling Drug, Robert K Bair, Paul E Dupont, B Woodrow Wyatt, July 8, 1986: US04599423 (9 worldwide citation)
  2. George Y Lesher, Chester J Opalka Jr, Donald F Page, Ruthann M McGarry: 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation. Sterling Drug, Robert K Bair, B Woodrow Wyatt, Paul E Dupont, August 14, 1984: US04465686 (10 worldwide citation)
  3. Herbicidal compositions containing phenylquinoxaline compounds. Shell Int Research, April 4, 1979: GB1543560-A (11 worldwide citation)
  4. Shinsaku Kobayashi, Katsuo Kamoshita, Shigeki Nagai, Takeo Honda, Kiroku Oda, Katsutoshi Fujii, Takashi Kobayashi, Mikio Kojima: 4-Anilinoquinazoline compounds and pharmaceutical compositions thereof. Sankyo, Ube, Frishauf Holtz Goodman & Woodward, August 7, 1984: US04464375 (23 worldwide citation)
  5. Shinsaku Kobayashi, Katsuo Kamoshita, Shigeki Nagai, Takeo Honda, Kiroku Oda, Katsutoshi Fujii, Takashi Kobayashi, Mikio Kojima: Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents. Sankyo Company, UBE, Frishauf Holtz Goodman & Woodward, March 30, 1982: US04322420 (34 worldwide citation)
  6. Robert N Young, Robert Zamboni: 2-[(substituted)-phenoxymethyl]quinolines. Merck Frosst Canada, Gabriel Lopez, Hesna J Pfeiffer, April 28, 1987: US04661499 (42 worldwide citation)
  7. Barker Andrew John, Davies David Huw: Therapeutic preparations containing quinazoline derivatives.. Ici, December 30, 1992: EP0520722-A1 (185 worldwide citation)
  8. November, 1992: WO20642